Event Brief
FDA approves breakthrough drug for metastatic pancreatic cancer
By The BriefBrief · Sources (3)
Filed: Aug 26, 2026 at 11:00 PM ET
Summary: The FDA approved daraxonrasib, to be sold as Rasonque by Revolution Medicines, for patients with metastatic pancreatic cancer. In a late-stage trial of 500 people, median overall survival nearly doubled to more than 13 months versus about 6.7 months with standard chemotherapy.
WHO: FDA; Revolution Medicines; Dr. Brian Wolpin (Dana-Farber Cancer Institute)
WHAT: Approval of daraxonrasib (Rasonque), a daily pill targeting multiple RAS protein forms, for metastatic pancreatic cancer.
WHEN: Aug 27, 2026
WHERE: CA
WHY: The FDA approved the drug after late-stage trial results showed substantially improved overall survival versus standard chemotherapy.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Sonic launches “Hotumn” fall drink lineup
Sonic
Aug 26, 2026 at 11:00 PM ET
🔒
Judge suspends charges for Downey man in golf club case
Los Angeles County
Aug 26, 2026 at 11:00 PM ET
🔒
Long Beach library fence cost tops $811,000
Long Beach
Aug 26, 2026 at 11:00 PM ET
🔒
L.A. deputies seek suspects in Target retail theft
Los Angeles County Sheriff’s Department
Aug 26, 2026 at 11:00 PM ET
🔒
